VivoSeq
Hematology

Haemophilia a

2

Pipeline Programs↗

11

Active Trials↗

6

Companies Involved↗

Haemophilia A is an early-stage landscape with 2 programs across 6 companies. The most active players are Novo Nordisk, Sanofi, CSL Behring. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

95/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novo Nordisk logo

Novo Nordisk

1 program

Phase 3Sanofi logo

Sanofi

1 program

Phase 3CSL Behring logo

CSL Behring

0 programs

PreclinicalOctapharma logo

Octapharma

0 programs

PreclinicalBayer logo

Bayer

0 programs

PreclinicalBioMarin Pharmaceutical logo

BioMarin Pharmaceutical

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 32

Efanesoctocog Alfa

Sanofi

Mim8

Novo Nordisk

Approved
No programs

Analysis

Trial Status

56

clinical trials

Completed39 · 70%
Recruiting7 · 13%
Unknown status4 · 7%
Active, not recruiting3 · 5%
Withdrawn1 · 2%
Enrolling by invitation1 · 2%
Other1 · 2%

Clinical Trials

Trial Activity

56 trials

Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients
Recruiting·Novo Nordisk logoNovo Nordisk·N/A·NCT06574984·900 enrolled
Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
Recruiting·Octapharma logoOctapharma·Phase 4·NCT05935358·28 enrolled
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
Recruiting·Octapharma logoOctapharma·Phase 4·NCT05936580·28 enrolled
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
Recruiting·Novo Nordisk logoNovo Nordisk·Phase 1·NCT07220564·20 enrolled
Haemophilia and Bone Loss - PHILEOS Study
Recruiting·—·N/A·NCT04384341·480 enrolled
Open-label, Long-term Safety and Efficacy Study of Mim8 in Participants With Haemophilia A With or Without Inhibitors
Recruiting·Novo Nordisk logoNovo Nordisk·Phase 3·NCT05685238·451 enrolled
A Multinational, Prospective, Open-label, Roll-over Study (LIBERTY) to Provide Post-trial Access to Treatment for Patients With Haemophilia A Who Have Completed a Previous Trial With Efanesoctocog Alfa
Recruiting·SSwedish Orphan Biovitrum·Phase 3·NCT06716814·104 enrolled
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors
Active, not recruiting·Novo Nordisk logoNovo Nordisk·Phase 3·NCT05135559·153 enrolled
Gene Therapy for Haemophilia A.
Active, not recruiting·UUniversity College, London·Phase 1/2·NCT03001830·14 enrolled
A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A
Active, not recruiting·BBaxalta now part of Shire·N/A·NCT04158934·207 enrolled
A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®
Enrolling by invitation·Novo Nordisk logoNovo Nordisk·N/A·NCT04574076·60 enrolled
Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.
Completed·Novo Nordisk logoNovo Nordisk·Phase 3·NCT01489111·36 enrolled
Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors
Completed·Novo Nordisk logoNovo Nordisk·N/A·NCT00703911·102 enrolled
A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors
Completed·Novo Nordisk logoNovo Nordisk·Phase 3·NCT05053139·281 enrolled
A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)
Completed·Novo Nordisk logoNovo Nordisk·Phase 3·NCT05878938·61 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)